Randomized phase II trial comparing IG-001 versus paclitaxel against first-line advanced ovarian cancer.

被引：0
|
作者：
Trieu, Vuong N. [1 ]
Choi, Monica [1 ]
Hwang, Larn [1 ]
D'Cruz, Osmond [1 ]
机构：
[1] Sorrento Therapeut, Irvine, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5590
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Development of personalized paclitaxel therapy (IG-001) for ovarian cancer.
    Hwang, Lam
    Hsiao, Chao
    Motamed, Kouros
    Vuong Trieu
    CANCER RESEARCH, 2013, 73 (08)
  • [2] A randomized, phase II trial of weekly paclitaxel versus weekly paclitaxel plus carboplatin for first-line metastatic breast cancer.
    Robert, N
    Loesch, D
    Lindquist, D
    Ratnam, S
    Hyman, W
    Whittaker, T
    Logie, K
    Kruger, S
    Pippen, J
    Liu, L
    Goldstein, L
    Asmar, L
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S129 - S129
  • [3] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    du Bois, A
    Lück, HJ
    Meier, W
    Adams, HP
    Möbus, V
    Costa, S
    Bauknecht, T
    Richter, B
    Warm, M
    Schröder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    Emons, G
    Wagner, U
    Kuhn, W
    Pfisterer, J
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17): : 1320 - 1330
  • [4] Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: A phase I trial
    Meerpohl, HG
    duBois, A
    Luck, HJ
    Kuhnle, H
    Mobus, V
    Kreienberg, R
    Bauknecht, T
    Kochli, O
    Bochtler, H
    Diergarten, K
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S17 - S22
  • [5] Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
    Fleming, Nicole D.
    Coleman, Robert L.
    Tung, Celestine
    Westin, Shannon N.
    Hu, Wei
    Sun, Yunjie
    Bhosale, Priya
    Munsell, Mark F.
    Sood, Anil K.
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 41 - 46
  • [6] Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: An interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group
    duBois, A
    Luck, HJ
    Meier, W
    Mobus, V
    Costa, S
    Richter, B
    Warm, M
    Bauknecht, T
    Schroder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    SEMINARS IN ONCOLOGY, 1997, 24 (05) : 44 - 52
  • [7] Phase II trial of bevacizumab with carboplatin and dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer
    Fleming, N. D.
    Coleman, R. L.
    Tung, C. S.
    Munsell, M. F.
    Sood, A. K.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 79 - 79
  • [8] Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
    Wu, Xiaohua
    Liu, Jihong
    Wang, Jing
    Wang, Li
    Lin, Zhongqiu
    Wang, Xiaobin
    Zhu, Jianqing
    Kong, Beihua
    Fei, Junwei
    Tang, Ying
    Xia, Bairong
    Liang, Zhiqing
    Wang, Ke
    Huang, Yi
    Zheng, Hong
    Lin, An
    Jiang, Kui
    Wang, Wei
    Wang, Xin
    Lou, Ge
    Pan, Hongming
    Yao, Shuzhong
    Li, Guiling
    Hao, Min
    Cai, Yunlang
    Chen, Xuejun
    Yang, Zhijun
    Chen, Youguo
    Wen, Hongwu
    Qu, Pengpeng
    Xu, Cong
    Hsieh, Chih-Yi
    NATURE MEDICINE, 2024, : 1612 - 1621
  • [9] Phase I trial of enzalutamide, gemcitabine, and nab-paclitaxel as a first-line treatment for advanced pancreatic cancer.
    Mahipal, Amit
    Springett, Gregory M.
    Burke, Nancy
    Neuger, Anthony
    Almhanna, Khaldoun
    Wapinsky, Georgine
    Bertels, Barbara
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer
    Friedlander, M.
    Buck, M.
    Wyld, D.
    Findlay, M.
    Fitzharris, B.
    De Souza, P.
    Davies, T.
    Kalimi, G.
    Allan, S.
    Perez, D.
    Harnett, P.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (02) : 350 - 358
12345